University of Michigan Researchers Use Gene Silencing to Alleviate Common Ataxia
In what researchers are calling a game changer for future ataxia treatments, a new study showed the ability to turn down the disease progression of the most common dominantly inherited ataxia.
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, affects about one in 20,000 people. There’s no disease-modifying therapy available, and patients slowly progress to an early death. A single gene mutation causes this neurodegenerative disease, making it an ideal target for a group of University of Michigan researchers.
For this preclinical study, University of Michigan researchers employed nucleotide-based gene silencing to target the SCA3 disease gene, ATXN3. They greatly reduced levels of the mutant RNA coded by the gene in a mouse model of the disease without any toxic effects.
Click here to read more.
2019 AANS/CNS Section on Pediatric Neurological Surgery Annual Meeting
Dec. 5-8, 2019; Scottsdale, Ariz.
Dec. 5-8, 2019; Mumbai, India
Miami Brain Symposium, Third Annual
Dec. 6, 2019; Miami
Surgical Spine Care: Removing Barriers to Patient Access, an ISASS Symposium
Dec. 6-7, 2019; New York
Georgia Neurosurgical Society Annual Fall Scientific Symposium
Dec. 6-7, 2019; Greensboro, Ga.